Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.

[1]  S. Goldsack,et al.  IN REAL-TIME , 2008 .

[2]  Kwangmeyung Kim,et al.  Hyaluronidase-sensitive SPIONs for MR/optical dual imaging nanoprobes , 2011 .

[3]  Kwangmeyung Kim,et al.  PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. , 2011, Biomaterials.

[4]  Kwangmeyung Kim,et al.  Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. , 2011, Bioconjugate chemistry.

[5]  Kwangmeyung Kim,et al.  Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis. , 2010, Biomaterials.

[6]  Ick Chan Kwon,et al.  Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. , 2010, Journal of Controlled Release.

[7]  Kinam Park,et al.  Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel. , 2010, International journal of pharmaceutics.

[8]  A. Bhatt,et al.  In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. , 2010, Macromolecular bioscience.

[9]  Amit Jain,et al.  The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. , 2010, Biomaterials.

[10]  Ick Chan Kwon,et al.  Self-assembled hyaluronic acid nanoparticles for active tumor targeting. , 2010, Biomaterials.

[11]  Kwangmeyung Kim,et al.  Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution , 2009 .

[12]  Jinwoo Cheon,et al.  Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology , 2009 .

[13]  Tae Gwan Park,et al.  Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. , 2009, Macromolecular bioscience.

[14]  Y. Nagasaki,et al.  A Smart Nanoprobe Based On Fluorescence‐Quenching PEGylated Nanogels Containing Gold Nanoparticles for Monitoring the Response to Cancer Therapy , 2009 .

[15]  Kitae E. Park,et al.  Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. , 2009, Molecular pharmaceutics.

[16]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[17]  Tae Gwan Park,et al.  Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes. , 2008, Biomaterials.

[18]  Kwangmeyung Kim,et al.  Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. , 2008, International journal of pharmaceutics.

[19]  N. Itano.  Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. , 2008, Journal of Biochemistry (Tokyo).

[20]  R. Stern.  Hyaluronidases in cancer biology. , 2008, Seminars in cancer biology.

[21]  T. Park,et al.  Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. , 2008, Bioconjugate chemistry.

[22]  Kwangmeyung Kim,et al.  Preparation and characterization of hyaluronic acid-based hydrogel nanoparticles , 2008 .

[23]  Kwangmeyung Kim,et al.  Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[24]  B. Maria,et al.  Targeting Hyaluronan Interactions in Malignant Gliomas and Their Drug-Resistant Multipotent Progenitors , 2008, Clinical Cancer Research.

[25]  Eun-Kyung Lim,et al.  Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment , 2008, Biotechnology and bioengineering.

[26]  Pushpa Mishra,et al.  Preparation and characterization of HA–PEG–PCL intelligent core–corona nanoparticles for delivery of doxorubicin , 2008 .

[27]  Taeghwan Hyeon,et al.  Bioinspired Surface Immobilization of Hyaluronic Acid on Monodisperse Magnetite Nanocrystals for Targeted Cancer Imaging , 2007, Advanced materials.

[28]  Ick Chan Kwon,et al.  Polymeric nanomedicine for cancer therapy , 2008 .

[29]  Pushpa Mishra,et al.  Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[30]  T. Park,et al.  Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. , 2007, Bioconjugate chemistry.

[31]  R. Price,et al.  Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. , 2007, Neoplasia.

[32]  Yu-Kyoung Oh,et al.  Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[33]  O. Herzberg,et al.  Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis. , 2007, Biochemistry.

[34]  R. Kannagi,et al.  Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. , 2007, The American journal of pathology.

[35]  M. Takahashi,et al.  CD44-dependent Intracellular and Extracellular Catabolism of Hyaluronic Acid by Hyaluronidase-1 and -2* , 2007, Journal of Biological Chemistry.

[36]  S. Wise.  Nanocarriers as an emerging platform for cancer therapy , 2007 .

[37]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.

[38]  M. Simpson.  Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. , 2006, The American journal of pathology.

[39]  D. Vynios,et al.  Hyaluronidase and CD44 hyaluronan receptor expression in squamous cell laryngeal carcinoma. , 2006, Biochimica et biophysica acta.

[40]  A. Rosato,et al.  HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. , 2006, Urologic oncology.

[41]  S. Ugurel,et al.  Lymphatic endothelium‐specific hyaluronan receptor LYVE‐1 is expressed by stabilin‐1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis , 2006, The Journal of pathology.

[42]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. J. Jedrzejas,et al.  Hyaluronidases: their genomics, structures, and mechanisms of action. , 2006, Chemical reviews.

[44]  V. Torchilin.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[45]  S. Nilsson,et al.  The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. , 2005, Experimental cell research.

[46]  V. Lokeshwar,et al.  HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. , 2005, Cancer research.

[47]  S. Sahoo,et al.  Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. , 2005, Molecular pharmaceutics.

[48]  V. Lokeshwar,et al.  HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. , 2005, Cancer research.

[49]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[50]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[51]  F. Jardin,et al.  Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B‐cell non‐Hodgkin lymphoma: Relationship with tumor aggressiveness , 2005, International journal of cancer.

[52]  Vladimir P Torchilin,et al.  Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[53]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[54]  U. Michl,et al.  Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. , 2004, European urology.

[55]  Ruxandra Gref,et al.  Polysaccharide-decorated nanoparticles. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[56]  D. Coradini,et al.  Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But , 2004, Clinical Cancer Research.

[57]  B. Toole,et al.  Hyaluronan: from extracellular glue to pericellular cue , 2004, Nature Reviews Cancer.

[58]  R. Stern,et al.  CD44 Interaction with Na+-H+ Exchanger (NHE1) Creates Acidic Microenvironments Leading to Hyaluronidase-2 and Cathepsin B Activation and Breast Tumor Cell Invasion* , 2004, Journal of Biological Chemistry.

[59]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[60]  T. Minko.  Drug targeting to the colon with lectins and neoglycoconjugates. , 2004, Advanced drug delivery reviews.

[61]  C. Lehr,et al.  Lectin-mediated drug targeting: history and applications. , 2004, Advanced drug delivery reviews.

[62]  D. Peer,et al.  Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.

[63]  F. Szoka,et al.  Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes , 2004, Cancer Research.

[64]  Kinam Park,et al.  Hydrotropic Solubilization of Paclitaxel: Analysis of Chemical Structures for Hydrotropic Property , 2003, Pharmaceutical Research.

[65]  R. Kannagi,et al.  Selective Expression and Functional Characteristics of Three Mammalian Hyaluronan Synthases in Oncogenic Malignant Transformation* , 2003, Journal of Biological Chemistry.

[66]  G. Turner,et al.  CD44 in inflammation and metastasis , 1997, Glycoconjugate Journal.

[67]  V. Lokeshwar,et al.  Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors , 2003, International journal of cancer.

[68]  P. Kristjansen,et al.  Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. , 2003, Oncology Report.

[69]  S. Ghatak,et al.  Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. , 2003, The American journal of pathology.

[70]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[71]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[72]  Hongzhe Sun,et al.  Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.

[73]  M. Rahmanian,et al.  Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors , 2002, International journal of cancer.

[74]  A. Csoka,et al.  Hyaluronidase reduces human breast cancer xenografts in SCID mice , 2002, International journal of cancer.

[75]  S. Ghatak,et al.  Hyaluronan Oligosaccharides Inhibit Anchorage-independent Growth of Tumor Cells by Suppressing the Phosphoinositide 3-Kinase/Akt Cell Survival Pathway* , 2002, The Journal of Biological Chemistry.

[76]  M. Oken,et al.  Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. , 2002, Blood.

[77]  Philip S Low,et al.  Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.

[78]  M. Simpson,et al.  Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. , 2002, The American journal of pathology.

[79]  A. Laquérriere,et al.  Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. , 2002, Anticancer research.

[80]  S. Hautmann,et al.  Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests , 2002, Cancer.

[81]  A. Madan,et al.  Expression of PH-20 in normal and neoplastic breast tissue. , 2002, The Journal of surgical research.

[82]  M. Tammi,et al.  Hyaluronan and Homeostasis: A Balancing Act* , 2002, The Journal of Biological Chemistry.

[83]  A. J. Day,et al.  Hyaluronan-binding Proteins: Tying Up the Giant* , 2002, The Journal of Biological Chemistry.

[84]  S. Nedvetzki,et al.  CD44 in Cancer , 2002, Critical reviews in clinical laboratory sciences.

[85]  D. Guidolin,et al.  Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 (intercellular adhesion molecule 1) invovement. , 2001, Arthritis and rheumatism.

[86]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[87]  F. Gao,et al.  Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. , 2001, Cancer research.

[88]  D. Ferguson,et al.  Mouse LYVE-1 Is an Endocytic Receptor for Hyaluronan in Lymphatic Endothelium* , 2001, The Journal of Biological Chemistry.

[89]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[90]  J. Minna,et al.  Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[91]  F. Szoka,et al.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. , 2001, Cancer research.

[92]  Bin Zhou,et al.  Identification of the Hyaluronan Receptor for Endocytosis (HARE)* , 2000, The Journal of Biological Chemistry.

[93]  V. Lokeshwar,et al.  Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. , 2000, The Journal of biological chemistry.

[94]  V. Kosma,et al.  Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. , 2000, The American journal of pathology.

[95]  Y. Yamaguchi,et al.  Lecticans: organizers of the brain extracellular matrix , 2000, Cellular and Molecular Life Sciences CMLS.

[96]  K. Endo,et al.  Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. , 2000, Journal of hepatology.

[97]  C. Öbek,et al.  Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. , 2000, The Journal of urology.

[98]  V. Assmann,et al.  The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. , 1999, Journal of cell science.

[99]  A. I. Yudin,et al.  Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. , 1999, Cancer research.

[100]  S. Goodison,et al.  CD44 cell adhesion molecules. , 1999, Molecular pathology : MP.

[101]  G. Prestwich,et al.  Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. , 1999, Bioconjugate chemistry.

[102]  C. Chauzy,et al.  Human breast‐cancer metastasis formation in a nude‐mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan‐binding sites in metastatic cells , 1999, International journal of cancer.

[103]  D. Coradini,et al.  Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti‐proliferative activity on a breast‐cancer cell line , 1999, International journal of cancer.

[104]  R. Kosaki,et al.  Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. , 1999, Cancer research.

[105]  V. Kosma,et al.  Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate , 1999, British Journal of Cancer.

[106]  D. Jackson,et al.  LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.

[107]  I. Stamenkovic,et al.  Inhibition of tumor growth in vivo by hyaluronan oligomers , 1998, International journal of cancer.

[108]  Stefanie Turley,et al.  The Hyaluronan Receptor RHAMM Regulates Extracellular-regulated Kinase* , 1998, The Journal of Biological Chemistry.

[109]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[110]  H. Naiki,et al.  Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. , 1998, Cancer research.

[111]  V. Kosma,et al.  Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. , 1998, Cancer research.

[112]  T. Laurent.  Biology and Medical Applications of Hyaluronan and its Derivatives , 1998 .

[113]  I. Stamenkovic,et al.  Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function , 1997, The Journal of experimental medicine.

[114]  M. Rahmanian,et al.  Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro. , 1997, Experimental cell research.

[115]  C. Chauzy,et al.  Increased hyaluronidase levels in breast tumor metastases , 1997, International journal of cancer.

[116]  Yoshihiko Yamada,et al.  Identification of Hyaluronan-binding Domains of Aggrecan* , 1997, The Journal of Biological Chemistry.

[117]  S. Martin,et al.  Soluble CD44 splice variants in metastasizing human breast cancer , 1997, International journal of cancer.

[118]  J. Fraser,et al.  Hyaluronan: its nature, distribution, functions and turnover , 1997, Journal of internal medicine.

[119]  J. Vilček,et al.  TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. , 1997, Cytokine & growth factor reviews.

[120]  I. Stamenkovic,et al.  Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. , 1997, Genes & development.

[121]  S. Cannistra,et al.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. , 1997, Cancer research.

[122]  N. Block,et al.  Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. , 1997, Cancer research.

[123]  M Tammi,et al.  Hyaluronan synthases. , 1997, The Journal of biological chemistry.

[124]  I. Campbell,et al.  Solution Structure of the Link Module: A Hyaluronan-Binding Domain Involved in Extracellular Matrix Stability and Cell Migration , 1996, Cell.

[125]  L. Orci,et al.  Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[126]  J. Willson,et al.  Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[127]  E. Turley,et al.  HA receptors: Regulators of signalling to the cytoskeleton , 1996, Journal of cellular biochemistry.

[128]  Viviane,et al.  Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. , 1996, The American journal of pathology.

[129]  N. Block,et al.  Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. , 1996, Cancer research.

[130]  O. Dapunt,et al.  Prognostic value of CD44 splice variant expression in ovarian cancer. , 1995, Oncology.

[131]  E. Danen,et al.  Expression of cd44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential , 1995, International journal of cancer.

[132]  H. Heinzl,et al.  Splice variants of CD44 in human cervical cancer stage IB to IIB. , 1995, Gynecologic oncology.

[133]  M. Zahalka,et al.  Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. , 1995, Journal of immunology.

[134]  W. Eisterer,et al.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. , 1995, Blood.

[135]  P. Herrlich,et al.  CD44 variant exon epitopes in primary breast cancer and length of survival , 1995, The Lancet.

[136]  D. Parker.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. , 1995, Lancet.

[137]  J. Oosting,et al.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins , 1994, The Lancet.

[138]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[139]  C. Figdor,et al.  De-novo expression of CD44 and survival in gastric cancer , 1993, The Lancet.

[140]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[141]  W. Knudson,et al.  Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. , 1993, Journal of cell science.

[142]  P. Herrlich,et al.  Prevention of tumor metastasis formation by anti-variant CD44 , 1993, The Journal of experimental medicine.

[143]  P. Heldin,et al.  Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts. , 1993, Cancer research.

[144]  B. Delpech,et al.  Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: Comparison between invasive and non‐invasive areas , 1992, International journal of cancer.

[145]  D. Nance,et al.  Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility [published erratum appears in J Cell Biol 1992 Aug;118(3):753] , 1992, The Journal of cell biology.

[146]  I. Hart,et al.  Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. , 1991, Cancer research.

[147]  I. Stamenkovic,et al.  Distinct effects of two CD44 isoforms on tumor growth in vivo , 1991, The Journal of experimental medicine.

[148]  H. Maibach,et al.  Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture. , 1991, The Journal of investigative dermatology.

[149]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[150]  M. Amiot,et al.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate‐bearing cells. , 1991, The EMBO journal.

[151]  I. Stamenkovic,et al.  CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.

[152]  S. Kumar,et al.  Sera of children with renal tumours contain low‐molecular‐mass hyaluronic acid , 1989, International journal of cancer.

[153]  L. Picker,et al.  A human lymphocyte homing receptor, the Hermes antigen, is related to cartilage proteoglycan core and link proteins , 1989, Cell.

[154]  Brian Seed,et al.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family , 1989, Cell.

[155]  V. Hascall,et al.  Correlated metabolism of proteoglycans and hyaluronic acid in bovine cartilage organ cultures. , 1988, The Journal of biological chemistry.

[156]  P. Comoglio,et al.  The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. , 1987, The Journal of biological chemistry.

[157]  B. E. Lacy,et al.  Characterization and identification of the hyaluronate binding site from membranes of SV-3T3 cells. , 1985, The Journal of biological chemistry.

[158]  I. Hampson,et al.  Angiogenesis induced by degradation products of hyaluronic acid. , 1985, Science.

[159]  B. Toole,et al.  Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[160]  P. Comoglio,et al.  A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton , 1984, The Journal of cell biology.

[161]  B. Toole,et al.  Physical characteristics of hyaluronate binding to the surface of simian virus 40-transformed 3T3 cells. , 1980, The Journal of biological chemistry.

[162]  B. Toole,et al.  Hyaluronate and invasiveness of the rabbit V2 carcinoma. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[163]  G. Gregoriadis.  Targeting of drugs , 1977, Nature.

[164]  T. Hardingham,et al.  The specific interaction of hyaluronic acid with cartillage proteoglycans. , 1972, Biochimica et biophysica acta.

[165]  M. Rapport,et al.  Isolation of a Crystalline Disaccharide, Hyalobiuronic Acid, from Hyaluronic Acid , 1951, Nature.

[166]  E. Chain,et al.  Identity of Hyaluronidase and Spreading Factor , 1940 .

[167]  Karl Meyer,et al.  THE POLYSACCHARIDE OF THE VITREOUS HUMOR , 1934 .